Ladarixin With Sotorasib in Advanced NSCLC - Phase II
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, study of twice-daily oral ladarixin in patients with advanced
KRAS G12C mutant non-small cell lung cancer (NSCLC) with sotorasib.